Abdin Alaa Din, Devenijn Machteld, Fulga Roxana, Langenbucher Achim, Seitz Berthold, Kaymak Hakan
Department of Ophthalmology, Saarland University Medical Center UKS, 66421 Homburg, Saar, Germany.
Internationale Innovative Ophthalmochirurgie, Breyer Kaymak Klabe Augenchirurgie, 40549 Düsseldorf, Nordrhein-Westfalen, Germany.
J Clin Med. 2023 Jul 24;12(14):4862. doi: 10.3390/jcm12144862.
To investigate the prevalence of geographic atrophy (GA) in advanced age-related macular degeneration (AMD) and the proportion of eyes that would meet the indication criteria for treatment with the first intravitreal anti-C3 agent (pegcetacoplan).
This retrospective cross-sectional study included all AMD patients who visited the Macular-Retina-Centre Oberkassel in 2021. Eyes were classified according to AMD stages. Eyes with GA were divided into two groups regarding foveal involvement. Baseline factors were compared between eyes with foveal GA (FGA) and eyes with non-foveal GA (NFGA) to identify predictive factors for foveal involvement.
A total of 2033 eyes from 1027 patients were included. AMD stage was early in 296 (14.5%) cases, intermediate in 368 (18.1%) cases, and advanced in 1249 (61.4%) cases. A total of 1204 (60%) eyes had GA [932 (77%) FGA and 272 (23%) NFGA], while 125 eyes (27.4% from eyes with advanced dry AMD) met the indication criteria for treatment with intravitreal pegcetacoplan. The proportion of eyes with neovascular AMD was significantly higher in the FGA group compared to the NFGA group [598 (64.2%) vs. 152 (55.8%), = 0.01].
At least a quarter of eyes with advanced AMD would be suitable for the upcoming intravitreal pegcetacoplan therapy. Foveal involvement of GA in advanced AMD seems to be more likely in neovascular AMD than in dry AMD.
研究晚期年龄相关性黄斑变性（AMD）中地图样萎缩（GA）的患病率以及符合首次玻璃体内注射抗C3药物（培西加可普坦）治疗指征标准的眼睛比例。
这项回顾性横断面研究纳入了2021年就诊于奥伯卡塞尔黄斑视网膜中心的所有AMD患者。根据AMD分期对眼睛进行分类。将患有GA的眼睛根据黄斑受累情况分为两组。比较黄斑区GA（FGA）眼和非黄斑区GA（NFGA）眼的基线因素，以确定黄斑受累的预测因素。
共纳入1027例患者的2033只眼睛。AMD分期为早期的有296例（14.5%），中期的有368例（18.1%），晚期的有1249例（61.4%）。共有1204只（60%）眼睛患有GA[932只（77%）FGA和272只（23%）NFGA]，而125只眼睛（占晚期干性AMD眼睛的27.4%）符合玻璃体内注射培西加可普坦治疗的指征标准。FGA组新生血管性AMD眼睛的比例显著高于NFGA组[598只（64.2%）对152只（55.8%），P = 0.01]。
至少四分之一的晚期AMD眼睛适合即将开展的玻璃体内注射培西加可普坦治疗。晚期AMD中，GA的黄斑受累在新生血管性AMD中似乎比在干性AMD中更常见。
